Conference

13th Annual Biomarkers Congress 2018

Meet with Q2 Solutions and learn how we can help optimize your product development life cycle

Manchester, UK | February 15, 2018 - February 16, 2018 | 08:00 - 17:00 Add to Calendar
Schedule a Meeting

About This Event

Employing a comprehensive suite of genomics expertise, molecular and protein-based platforms, Q2 Solutions’ end-to-end solutions help ensure the rapid identification, designing and/or validating of biomarkers.

With an exponential growth in the area of personalized precision medicine and in particular immuno-oncology, Q2 Solutions’ technology platforms, bioinformatics and genomic know-how® can help you in identifying the right mechanism of action or specific disease indication, in choosing the right platform for developing a robust assay. We provide you with an optimal path to co-develop your companion diagnostic (CDx) with clinical development of the therapeutic, regulatory submission and market launch.  Our integrated approach is designed so you optimize time to market and commercial success.

With clinical and scientific experts spanning nearly every major disease area, our services integrate the early clinical development, clinical development, pre-launch and commercialization stages of your drug development process. 

Schedule a meeting to learn how our world-renowned central lab capabilities can help you integrate biomarkers across your development plan, from discovery, clinical development, and commercialization into leveraging precision medicine.

We look forward to meeting you in Manchester, UK.

Related Services:

Register for Event

Companion Diagnostic Expertise

Learn how we can ensure success in your next companion diagnostic development program

Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Read More